Related references
Note: Only part of the references are listed.Drug Repositioning in Oncology
Marissa B. Serafin et al.
AMERICAN JOURNAL OF THERAPEUTICS (2021)
Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant
Jessi K. Edwards et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)
Role of sensory neurons, neuroimmune pathways, and transient receptor potential vanilloid 1 (TRPV1) channels in a murine model of breast cancer metastasis
Nuray Erin
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Aprepitant for Cough Suppression in Advanced Lung Cancer A Randomized Trial
Vanita Noronha et al.
CHEST (2020)
Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib
Joanna J. Chmielinska et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2020)
The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways
Hossein Javid et al.
MOLECULAR BIOLOGY REPORTS (2020)
Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects
Meng-Jie Yang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
The NK-1R Antagonist Aprepitant Prevents LPS-Induced Oxidative Stress and Inflammation in RAW264.7 Macrophages
Xiao-nan Zhao et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
TGF beta regulates NK1R-Tr to affect the proliferation and apoptosis of breast cancer cells
Lushan Wang et al.
LIFE SCIENCES (2020)
Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression
Fariba Mohammadi et al.
MOLECULAR BIOLOGY REPORTS (2020)
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
Miguel Munoz et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Design and Characterization of Phosphatidylcholine-Based Solid Dispersions of Aprepitant for Enhanced Solubility and Dissolution
Sooho Yeo et al.
PHARMACEUTICS (2020)
A novel effect of Aprepitant: Protection for cisplatin-induced nephrotoxicity and hepatotoxicity
Harun Un et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo
Hongzhang Wu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors
Pawel K. Halik et al.
MOLECULES (2020)
Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists
A. Molinos-Quintana et al.
INVESTIGATIONAL NEW DRUGS (2019)
Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells
Miris Dikmen et al.
ANTI-CANCER DRUGS (2019)
SP/NK-1R promotes gallbladder cancer cell proliferation and migration
Xue-Ting Deng et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Miguel Munoz et al.
LETTERS IN DRUG DESIGN & DISCOVERY (2019)
Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer
Monireh Davoodian et al.
MOLECULAR BIOLOGY REPORTS (2019)
The neurokinin-1 receptor antagonist aprepitant ameliorates oxidized LDL-induced endothelial dysfunction via KLF2
Jianghua Zheng et al.
MOLECULAR IMMUNOLOGY (2019)
Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients
Jaume Mora et al.
PEDIATRIC BLOOD & CANCER (2019)
SP promotes cell proliferation in esophageal squamous cell carcinoma through the NK1R/Hes1 axis
Fei Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy
Erlend Skaga et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes
Xiaoping Liu et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2019)
The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells
Hossein Javid et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2019)
Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma
Giovanna Giagnuolo et al.
PLOS ONE (2019)
Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation
K. Agelopoulos et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload
Chentao Ge et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Neurokinin-1 Receptor Antagonists against Hepatoblastoma
Miguel Munoz et al.
CANCERS (2019)
The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy
Agnieszka Majkowska-Pilip et al.
PHARMACEUTICS (2019)
Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial
Jie Xiong et al.
ADVANCES IN THERAPY (2019)
MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis
Lufang Zhang et al.
CELL PROLIFERATION (2019)
MicroRNA-22 inhibits proliferation, invasion and metastasis of breast cancer cells through targeting truncated neurokinin-1 receptor and ERα
Xiaobin Liu et al.
LIFE SCIENCES (2019)
Evaluation of aprepitant and fosaprepitant in pediatric patients
Yoshimasa Saito et al.
PEDIATRICS INTERNATIONAL (2019)
Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists
Jendrik Schoeppe et al.
NATURE COMMUNICATIONS (2019)
Emerging targets for cough therapies; NK1 receptor antagonists
Huda Badri et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2019)
miR-206 Promotes Cancer Progression by Targeting Full-Length Neurokinin-1 Receptor in Breast Cancer
Yu Zhou et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2019)
Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report
Miguel Munoz et al.
MOLECULAR AND CLINICAL ONCOLOGY (2019)
Perioperative events influence cancer recurrence risk after surgery
Jonathan G. Hiller et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: a novel therapeutic potential for aprepitant
Samaneh Bayati et al.
ANTI-CANCER DRUGS (2018)
MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells
Chumei Huang et al.
THERANOSTICS (2018)
Biological Mechanisms of Cancer-Induced Depression
Kimberly Young et al.
FRONTIERS IN PSYCHIATRY (2018)
Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P
Esra Nizam et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant
Davood Bashash et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)
Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in endometrial cancer
Naghmeh Gharaee et al.
MOLECULAR BIOLOGY REPORTS (2018)
Aprepitant for the Treatment of Pruritus in Sezary Syndrome: A Randomized Crossover Clinical Trial
John A. Zic et al.
JAMA DERMATOLOGY (2018)
Neuropeptide-induced modulation of carcinogenesis in a metastatic breast cancer cell line (MDA-MB-231LUC+)
Silvia Gutierrez et al.
CANCER CELL INTERNATIONAL (2018)
Targeting tachykinin receptors in neuroblastoma
Anton G. Henssen et al.
ONCOTARGET (2017)
Ketamine suppresses the substance P-induced production of IL-6 and IL-8 by human U373MG glioblastoma/astrocytoma cells
Keisuke Yamaguchi et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)
β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G2/M phase transition
Yi-Xin Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis
Susmit Suvas
JOURNAL OF IMMUNOLOGY (2017)
Cancer and Venous Thromboembolic Disease: A Review
Eoin Donnellan et al.
ONCOLOGIST (2017)
Expression of Truncated Neurokinin-1 Receptor in Childhood Neuroblastoma is Independent of Tumor Biology and Stage
Alexandra Pohl et al.
ANTICANCER RESEARCH (2017)
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells
Richard E. Kast et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Therapeutic Innovations for Targeting Hepatoblastoma
Agnes Garnier et al.
ANTICANCER RESEARCH (2016)
Neurokinin-1 receptor mediated breast cancer cell migration by increased expression of MMP-2 and MMP-14
Jingyi Li et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2016)
Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Aktip53 axis in pre-B acute lymphoblastic leukemia cells
Samaneh Bayati et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
Substance P Promotes the Progression of Endometrial Adenocarcinoma
Jing Ma et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
Human hemokinin-1 promotes migration of melanoma cells and increases MMP-2 and MT1-MMP expression by activating tumor cell NK1 receptors
Yixin Zhang et al.
PEPTIDES (2016)
High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis
Xiao-Yi Chen et al.
ONCOTARGETS AND THERAPY (2016)
Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance
Prema Robinson et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Neuropeptide Levels as well as Neprilysin Activity Decrease in Renal Cell Carcinoma
Nuray Erin et al.
CANCER MICROENVIRONMENT (2016)
Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults
Pablo Tebas et al.
AIDS (2015)
Elevated SP/NK-1R in esophageal carcinoma promotes esophageal carcinoma cell proliferation and migration
Jiaqiang Dong et al.
GENE (2015)
Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells
Agnes Garnier et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
The substance PINK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs
Miguel Munoz et al.
JOURNAL OF BIOSCIENCES (2015)
Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma
Matthias Ilmer et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Role of neurotransmitter Substance P in progression of oral squamous cell carcinoma
Riffat Mehboob et al.
PATHOLOGY RESEARCH AND PRACTICE (2015)
Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth
Fanyin Meng et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2014)
Involvement of substance P and the NK-1 receptor in human pathology
Miguel Munoz et al.
AMINO ACIDS (2014)
Depression as a Risk Factor for Cancer: From Pathophysiological Advances to Treatment Implications
M. Beatriz Currier et al.
ANNUAL REVIEW OF MEDICINE, VOL 65 (2014)
Mitochondrial Ca2+ influx targets cardiolipin to disintegrate respiratory chain complex II for cell death induction
M-S Hwang et al.
CELL DEATH AND DIFFERENTIATION (2014)
The proinflammatory peptide substance P promotes blood-brain barrier breaching by breast cancer cells through changes in microvascular endothelial cell tight junctions
Pedro L. Rodriguez et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts
Miguel Munoz et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer
Miguel Munoz et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo
Michael Berger et al.
JOURNAL OF HEPATOLOGY (2014)
EVALUATING THE ROLE OF SUBSTANCE P IN THE GROWTH OF BRAIN TUMORS
E. Harford-Wright et al.
NEUROSCIENCE (2014)
TACHYKININS AND THEIR RECEPTORS: CONTRIBUTIONS TO PHYSIOLOGICAL CONTROL AND THE MECHANISMS OF DISEASE
Martin S. Steinhoff et al.
PHYSIOLOGICAL REVIEWS (2014)
Treatment with the NK1 Antagonist Emend Reduces Blood Brain Barrier Dysfunction and Edema Formation in an Experimental Model of Brain Tumors
Elizabeth Harford-Wright et al.
PLOS ONE (2014)
NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer
Kate M. Lewis et al.
ANTI-CANCER DRUGS (2013)
Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer
Yunli Zhou et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Substance P Autocrine Signaling Contributes to Persistent HER2 Activation That Drives Malignant Progression and Drug Resistance in Breast Cancer
Susana Garcia-Recio et al.
CANCER RESEARCH (2013)
Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion
Kate M. Lewis et al.
CLINICAL & EXPERIMENTAL METASTASIS (2013)
Safety of neurokinin-1 receptor antagonists
Miguel Munoz et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Neurokinin-1 Receptor Directly Mediates Glioma Cell Migration by Up-regulation of Matrix Metalloproteinase-2 (MMP-2) and Membrane Type 1-Matrix Metalloproteinase (MT1-MMP)
Lingyun Mou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer
Kiyoshi Misawa et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Neurotransmitter Substance P Mediates Pancreatic Cancer Perineural Invasion via NK-1R in Cancer Cells
Xuqi Li et al.
MOLECULAR CANCER RESEARCH (2013)
Expression of proliferative markers in ameloblastomas and malignant odontogenic tumors
D. Otero et al.
ORAL DISEASES (2013)
Involvement of substance P and the NK-1 receptor in cancer progression
Miguel Munoz et al.
PEPTIDES (2013)
NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011
Miguel Munoz et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines
Miguel Munoz et al.
INVESTIGATIONAL NEW DRUGS (2012)
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2
Cristina Mayordomo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists
Miguel Munoz et al.
PEPTIDES (2012)
Activation of vagus nerve by semapimod alters substance P levels and decreases breast cancer metastasis
Nuray Erin et al.
REGULATORY PEPTIDES (2012)
FoxM1 Promotes β-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis
Nu Zhang et al.
CANCER CELL (2011)
Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells
Fan Feng et al.
CELL BIOLOGY INTERNATIONAL (2011)
The NK-1 Receptor: A New Target in Cancer Therapy
Miguel Munoz et al.
CURRENT DRUG TARGETS (2011)
Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer
Earl Gillespie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Endostatin enhances radioresponse in breast cancer cells via alteration of substance P levels
Esra Arslan Aydemir et al.
ONCOLOGY LETTERS (2011)
The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma
Gerlinde Egerer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
CD10-bearing fibroblast inhibits matrigel invasive potency of interleukin-1α-producing squamous cell carcinoma by diminishing substance P levels in the tumor microenvironment
Lining Xie et al.
CANCER SCIENCE (2010)
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
D. Cordier et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Somatostatin, substance P and calcitonin gene-related peptide-positive intramural nerve structures of the human large intestine affected by carcinoma
Janusz Godlewski et al.
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA (2010)
The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug
Miguel Munoz et al.
INVESTIGATIONAL NEW DRUGS (2010)
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug
R. E. Kast
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2010)
The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines
Miguel Munoz et al.
LABORATORY INVESTIGATION (2010)
Treatment of acute myeloid leukemia
Elihu H. Estey
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Substance P and NK-1R expression in oral precancerous epithelium
M. A. Gonzalez-Moles et al.
ONCOLOGY REPORTS (2009)
Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation
Sarah Jones et al.
BLOOD (2008)
Cell motility through plasma membrane blebbing
Oliver T. Fackler et al.
JOURNAL OF CELL BIOLOGY (2008)
HIF-1α is up-regulated in activated mast cells by a process that involves calcineurin and NFAT
Aurelia Walczak-Drzewiecka et al.
JOURNAL OF IMMUNOLOGY (2008)
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
A. A. Khorana et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant
Ian Olver et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2007)
Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder
M Keller et al.
BIOLOGICAL PSYCHIATRY (2006)
Metastasis: a question of life or death
P Mehlen et al.
NATURE REVIEWS CANCER (2006)
The expression of neurokinin-1 and preprotachykinin-1 in breast cancer cells depends on the relative degree of invasive and metastatic potential
Tammy A. Castro et al.
CLINICAL & EXPERIMENTAL METASTASIS (2005)
The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies
G Morgan et al.
CLINICAL ONCOLOGY (2004)
Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs
K Lang et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Depression and cancer: Mechanisms and disease progression
D Spiegel et al.
BIOLOGICAL PSYCHIATRY (2003)
Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-κB site on its promoter
S Simeonidis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Substance P
S Harrison et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2001)
Role of NK1 receptors on cisplatin-induced nephrotoxicity in the rat
AB Alfieri et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2000)
The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
FD Tattersall et al.
NEUROPHARMACOLOGY (2000)
Share Paper
